Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRETE: Enoxaparin Prophylaxis Against Catheter-associated Thrombosis in Critically Ill Children
NCT04924322Phase 3Recruiting
- Sponsor
- Yale University
- Start
- May 2022
- Primary completion
- Apr 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of enoxaparin in deep venous thrombosis (DVT), sponsored by Yale University. Started May 2022; status: recruiting.
02
Drugs
enoxaparin
03
Conditions
deep venous thrombosis (DVT)
Beyond the preview
Go deeper on NCT04924322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924322.